BACKGROUND: Leukocyte esterase (LE) strip test is an accurate marker for diagnosing periprosthetic joint infection (PJI). This study aims to determine if LE is a good predictor of persistent infection and/or subsequent failure in patients undergoing reimplantation. METHODS: This single-institution study prospectively recruited and retrospectively analyzed 109 patients who underwent two-stage exchange treatment of PJI, from 2009-2016, and had an LE test performed at time of reimplantation. LE results of "2+" were considered positive. Ninety-five patients had 90-day minimum follow-up to assess treatment failure, defined by Delphi criteria. Eighteen patients were excluded due to blood contamination of LE test, resulting in a final cohort of 77 patients (mean follow-up 1.76 years). RESULTS: Of the final cohort, 19 patients (24.7%) experienced subsequent failure. At reimplantation, LE test was positive in 22.2% of culture-positive and 4.4% of culture-negative cases. The LE test was negative in all patients who had not failed at latest follow-up, yielding sensitivity, specificity, positive predictive value, negative predictive value, and AUC of 26.3%, 100%, 100%, 87.5%, and 0.632, respectively; in comparison, MSIS criteria respectively yielded 25.0%, 87.3%, 27.6%, 85.8%, and 0.562 (P = .01 for specificity). Kaplan-Meier curves revealed higher failure rate in patients who had a positive LE test at time of reimplantation (P < .001). CONCLUSION: There is a dire need for an accurate diagnostic test to determine optimal timing of reimplantation in patients undergoing surgical treatment for PJI. The current study suggests that a positive LE test may be indicative of persistence of infection and results in a higher rate of subsequent failure.
BACKGROUND: Leukocyte esterase (LE) strip test is an accurate marker for diagnosing periprosthetic joint infection (PJI). This study aims to determine if LE is a good predictor of persistent infection and/or subsequent failure in patients undergoing reimplantation. METHODS: This single-institution study prospectively recruited and retrospectively analyzed 109 patients who underwent two-stage exchange treatment of PJI, from 2009-2016, and had an LE test performed at time of reimplantation. LE results of "2+" were considered positive. Ninety-five patients had 90-day minimum follow-up to assess treatment failure, defined by Delphi criteria. Eighteen patients were excluded due to blood contamination of LE test, resulting in a final cohort of 77 patients (mean follow-up 1.76 years). RESULTS: Of the final cohort, 19 patients (24.7%) experienced subsequent failure. At reimplantation, LE test was positive in 22.2% of culture-positive and 4.4% of culture-negative cases. The LE test was negative in all patients who had not failed at latest follow-up, yielding sensitivity, specificity, positive predictive value, negative predictive value, and AUC of 26.3%, 100%, 100%, 87.5%, and 0.632, respectively; in comparison, MSIS criteria respectively yielded 25.0%, 87.3%, 27.6%, 85.8%, and 0.562 (P = .01 for specificity). Kaplan-Meier curves revealed higher failure rate in patients who had a positive LE test at time of reimplantation (P < .001). CONCLUSION: There is a dire need for an accurate diagnostic test to determine optimal timing of reimplantation in patients undergoing surgical treatment for PJI. The current study suggests that a positive LE test may be indicative of persistence of infection and results in a higher rate of subsequent failure.
Authors: Linsen T Samuel; Assem A Sultan; Matthew Kheir; Jesus Villa; Preetesh Patel; Javad Parvizi; Carlos A Higuera Journal: Clin Orthop Relat Res Date: 2019-07 Impact factor: 4.176
Authors: Charlotte Bielefeld; Harald Engler; Marcus JÄger; Alexander Wegner; Dennis Wassenaar; Andre Busch Journal: In Vivo Date: 2021 Mar-Apr Impact factor: 2.155
Authors: Sufian S Ahmad; Michael T Hirschmann; Roland Becker; Ahmed Shaker; Atesch Ateschrang; Marius J B Keel; Christoph E Albers; Lukas Buetikofer; Sithombo Maqungo; Ulrich Stöckle; Sandro Kohl Journal: Knee Surg Sports Traumatol Arthrosc Date: 2018-03-20 Impact factor: 4.342
Authors: Tejbir S Pannu; Jesus M Villa; Charles Engh; Arpan Patel; Brett R Levine; Nicolas S Piuzzi; Carlos A Higuera; Aldo M Riesgo Journal: Clin Orthop Relat Res Date: 2021-07-01 Impact factor: 4.755
Authors: Thomas Bauer; Simon Marmor; Idir Ghout; Elsa Salomon; Faten El Sayed; Beate Heym; Martin Rottman; Jean-Louis Gaillard; Anne-Laure Roux Journal: J Bone Jt Infect Date: 2019-09-26
Authors: Elena De Vecchi; Carlo Luca Romanò; Roberta De Grandi; Laura Cappelletti; Francesca Villa; Lorenzo Drago Journal: Int J Immunopathol Pharmacol Date: 2018 Mar-Dec Impact factor: 3.219